Osteoarthritis: Structural Endpoints for the Development of Drugs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 23, 2018
May 15, 2020
8fba9dbf-fb3b-42a9-8837-a2ce4870eba1
Related Documents
Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology
Guidance DocumentJanuary 17, 2025Office of the Commissioner
Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment
Guidance DocumentSeptember 28, 2023Office of the Commissioner
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Guidance DocumentJanuary 12, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.